Fatereh Baharlouei Yancheshmeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fatereh Baharlouei Yancheshmeh has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Amirreza Khalaji
Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
1 shared publication - Arya Khorram
Department of Laboratory Sciences, School of Allied Medical Sciences, Alborz University of Medical Sciences, Karaj, Iran
1 shared publication - Atefeh Amerizadeh
Cardiac Rehabilitation Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
1 shared publication - Azam Soleimani
Cardiac Rehabilitation Research Center, Cardiovascular Research Institute Isfahan University of Medical Sciences Isfahan Iran
1 shared publication - Fatemeh Farham
Department of Headache, Iranian center of Neurological Research, Neurosciences Institute, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication - Fatemeh Vatankhah
Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
1 shared publication
Latest Publications
- Open Access
- 24 October 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (43) , e45304
QTc prolongation and torsades de pointes (TdP) in individuals undergoing methadone maintenance treatment (MMT): A systematic review and meta-analysis
Background: The incidence of corrected QT interval (QTc) prolongation and torsades de pointes (TdP) in individuals undergoing methadone maintenance treatment (MMT) is a significant concern, as studies indicate that methadone can lead to these cardiac complications. Methods: A systematic search was performed across various databases including PubMed, Scopus, and Embase from January 2000 to July 2025. Risk of bias was assessed using the Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) for observational studies. Results: Twenty-two observational studies were included. The pooled mean age of patients undergoing MMT across the included studies was 40.8 years (95% confidence interval [CI]: 37.9–43.8). The overall pooled proportion of male participants across the included studies was 73% (95% CI: 66–81%). Incidence of QTc prolongation among patients on MMT showed a prevalence of 34% (95% CI: 24–43%). The pooled incidence of TdP was 2% (95% CI: 0–5%) after removing outlier study. The majority of evidence supports a dose-dependent relationship between methadone and QTc prolongation, though TdP remains rare and inconsistently linked to dose. This underscores the need for individualized dose titration and electrocardiogram monitoring, especially at higher daily doses (>100 mg). Conclusion: MMT is associated with a substantial risk of QTc prolongation and a low but clinically relevant risk of TdP. Careful dose adjustment and regular electrocardiogram monitoring, particularly at higher doses, are essential to minimize cardiac complications.
- 24 October 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (43) , e45304
Open AccessQTc prolongation and torsades de pointes (TdP) in individuals undergoing methadone maintenance treatment (MMT): A systematic review and meta-analysis
Background: The incidence of corrected QT interval (QTc) prolongation and torsades de pointes (TdP) in individuals undergoing methadone maintenance treatment (MMT) is a significant concern, as studies indicate that methadone can lead to these cardiac complications. Methods: A systematic search was performed across various databases including PubMed, Scopus, and Embase from January 2000 to July 2025. Risk of bias was assessed using the Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) for observational studies. Results: Twenty-two observational studies were included. The pooled mean age of patients undergoing MMT across the included studies was 40.8 years (95% confidence interval [CI]: 37.9–43.8). The overall pooled proportion of male participants across the included studies was 73% (95% CI: 66–81%). Incidence of QTc prolongation among patients on MMT showed a prevalence of 34% (95% CI: 24–43%). The pooled incidence of TdP was 2% (95% CI: 0–5%) after removing outlier study. The majority of evidence supports a dose-dependent relationship between methadone and QTc prolongation, though TdP remains rare and inconsistently linked to dose. This underscores the need for individualized dose titration and electrocardiogram monitoring, especially at higher daily doses (>100 mg). Conclusion: MMT is associated with a substantial risk of QTc prolongation and a low but clinically relevant risk of TdP. Careful dose adjustment and regular electrocardiogram monitoring, particularly at higher doses, are essential to minimize cardiac complications.